Oramed Pharmaceuticals Inc (ORMP)

$3.46

+0.16

(+4.85%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Oramed Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 682.0K → 674.0K (in $), with an average decrease of 0.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.19M → -3.22M (in $), with an average decrease of 169.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 74.4% return, outperforming this stock by 9.6%

Performance

  • $3.29
    $3.51
    $3.46
    downward going graph

    4.91%

    Downside

    Day's Volatility :6.27%

    Upside

    1.42%

    downward going graph
  • $1.67
    $5.25
    $3.46
    downward going graph

    51.73%

    Downside

    52 Weeks Volatility :68.19%

    Upside

    34.1%

    downward going graph

Returns

PeriodOramed Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
57.27%
12.8%
0.0%
6 Months
6.79%
10.8%
0.0%
1 Year
66.35%
15.1%
-6.4%
3 Years
-70.35%
30.2%
-19.6%

Highlights

Market Capitalization
139.6M
Book Value
$3.7
Earnings Per Share (EPS)
-0.41
PEG Ratio
0.0
Wall Street Target Price
4.25
Profit Margin
0.0%
Operating Margin TTM
-1070.36%
Return On Assets TTM
-6.84%
Return On Equity TTM
-11.24%
Revenue TTM
2.0M
Revenue Per Share TTM
0.05
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
2.7M
EBITDA
-21.5M
Diluted Eps TTM
-0.41
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.31
EPS Estimate Next Year
-0.26
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.18

Analyst Recommendation

Hold
    0
    0%Buy
    57%Hold
    42%Sell
Based on 7 Wall street analysts offering stock ratings for Oramed Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
4
4
4
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 22.83%

Current $3.46
Target $4.25

Technicals Summary

Sell

Neutral

Buy

Oramed Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
52.42%
6.79%
66.35%
-70.35%
-70.35%
Moderna, Inc.
Moderna, Inc.
-6.18%
-13.82%
-30.24%
-34.99%
345.54%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.41%
18.17%
29.48%
116.51%
133.41%
Novo Nordisk A/s
Novo Nordisk A/s
16.81%
32.44%
72.22%
241.3%
399.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
22.87%
49.66%
101.95%
130.83%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
NA
NA
0.0
-0.31
-0.11
-0.07
NA
3.7
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.46
-0.22
-0.07
NA
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.77
27.77
1.97
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.7
45.7
4.49
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.77
30.77
0.58
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc
Hold
$139.6M
-70.35%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.9B
345.54%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$105.9B
133.41%
27.77
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.7B
399.49%
45.7
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.2B
130.83%
30.77
36.68%

Institutional Holdings

  • BML Capital Management LLC

    1.94%
  • Renaissance Technologies Corp

    0.85%
  • Rathbone Brothers PLC

    0.72%
  • Two Sigma Advisers, LLC

    0.41%
  • Goldman Sachs Group Inc

    0.38%
  • GSA Capital Partners LLP

    0.22%

Corporate Announcements

  • Oramed Pharmaceuticals Inc Earnings

    Oramed Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg

Organization
Oramed Pharmaceuticals Inc
Employees
0
CEO
Mr. Nadav Kidron Esq.
Industry
Health Technology

FAQs